Cognitive & Neuro Regulation

Cerebrolysin (Brain-Derived Peptide Cocktail)

For Research Use Only. Not for Human or Veterinary Use.

Overview

Cerebrolysin is not a single molecule but a standardised mixture of low-molecular-weight peptides and free amino acids produced by enzymatic breakdown of purified porcine brain protein. The peptide fraction (≤ ~10,000 Da) is studied for neurotrophic-factor-like activity — mimicking factors such as BDNF, GDNF and CNTF — in neurodegeneration and CNS-injury research. It is supplied as a sterile solution and is a research material.

Composition Profile

Because Cerebrolysin is a biologically-derived mixture, it is described by composition rather than a single formula.

PropertyValue
CAS numberN/A (biologically-derived mixture)
ClassNeurotrophic peptide cocktail
Composition≈ 80% low-MW peptides (≤ 10,000 Da), ≈ 20% free amino acids
Molecular-weight range≈ 120–10,000 Da (mostly 500–3,000 Da)
SourceStandardised porcine brain protein hydrolysate
FormSterile isotonic solution (ampoules)
Cerebrolysin at a glance
Class
Neurotrophic peptide cocktail
Type
Standardised mixture (not a single molecule)
Research status
Clinical (multiple trials for CNS indications)
Study routes
Intravenous (slow infusion), IM
Key feature
Neurotrophic-factor-like activity

Mechanism of Action

Cerebrolysin’s peptide fraction is studied for reproducing the actions of endogenous neurotrophic factors, supporting neuronal survival, synaptic plasticity and repair. Because it is a mixture, its activity is attributed to several peptide components acting on overlapping neurotrophic pathways rather than to one defined target.

ComponentDetail
Neurotrophic mimicryBDNF-, GDNF-, CNTF- and NT-3-like activity
NeuroprotectionAnti-apoptotic and antioxidant effects in models
Synaptic plasticitySupport for synapse formation and maintenance
NeurogenesisStudied for promoting neural repair
Amyloid researchExplored in neurodegeneration models

Pharmacology

ParameterValue
Half-life (t½)≈ 4–6 h (mixture)
Route of administrationIntravenous (slow infusion), intramuscular
Protein content≈ 50 mg peptide fraction per mL (typical preparation)
MetabolismProteolytic degradation of peptide components
EliminationRenal (peptide fragments and amino acids)

Research Evidence

Cerebrolysin has a substantial clinical literature across CNS indications. Representative research areas are named below; specific numerical outcomes are not restated here as claims.

Research areaFocusReference
Ischemic-stroke recoveryNeurological and functional outcomesCerebrolysin clinical literature
Alzheimer’s / dementiaCognitive endpointsCerebrolysin clinical literature
Traumatic brain injuryRecovery and neuroprotectionCerebrolysin clinical literature

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Improved outcomes in ischemic-stroke researchclinical trialsCerebrolysin literature
Cognitive endpoints in dementia researchclinical trialsCerebrolysin literature
Neurotrophic-factor-like neuroprotectionpreclinical modelsCerebrolysin literature

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Handling Reference

Handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research range (literature)≈ 5–20 mL per administration, in study protocols
FormPre-mixed sterile solution (no reconstitution)
RouteIntravenous (slow infusion) or intramuscular
Storage15–25°C, sealed, protected from light
Do not useIf the solution is discolored or contains particulates

Safety Profile

Published research observations, provided for reference only. This material is not for human or veterinary use.

CategoryPublished observations
TolerabilityGenerally well tolerated in reported studies
Infusion-relatedRapid infusion may cause transient warmth / dizziness
Origin notePorcine-derived biological product
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateSterile, clear aqueous solution
pH≈ 6.5–7.0
TonicityIsotonic
CompositionPeptides ≤ 10,000 Da + free amino acids
StorageRoom temperature (15–25°C), protected from light

Production Process

Cerebrolysin is manufactured by standardised enzymatic hydrolysis of purified porcine brain protein, followed by filtration and standardisation of the low-molecular-weight peptide fraction — a biological-processing route, not chemical synthesis.

  • Purified porcine brain protein as starting material
  • Controlled enzymatic (proteolytic) hydrolysis
  • Filtration to the low-molecular-weight fraction (≤ ~10,000 Da)
  • Standardisation, sterile filtration and filling into ampoules

Analytical Methods

Because Cerebrolysin is a standardised biological mixture rather than a single molecule, quality control is about batch-to-batch consistency — the peptide fingerprint, molecular-weight distribution and total peptide/amino-acid content — plus the usual checks for an injectable solution.

MethodPurposeTypical result
HPLC peptide fingerprintingBatch consistencyReproducible peptide profile
Size-exclusion chromatography (SEC)Molecular-weight distribution≤ ~10,000 Da fraction (mostly 500–3,000)
Amino-acid analysisFree-amino-acid contentWithin specification (~20%)
Total protein / peptide assayConcentration≈ 50 mg peptide/mL (typical)
LAL assayEndotoxinWithin limit for an injectable
pHSolution pH≈ 6.5–7.0
OsmolalityIsotonicityIsotonic
SterilityMicrobial safetySterile
  • No single-compound identity is defined; consistency is judged against a reference fingerprint and the MW-distribution profile.

Stability Data

ConditionDurationResult
Sealed ampoule, 15–25°C, darkPer labelled shelf-lifeStable
Sealed ampoule, brief 2–8°CShort-termAcceptable; do not freeze
After openingUse promptlySingle use — do not store opened ampoules
Diluted in infusion fluidUse within hoursPrepare immediately before use
Light exposure—Protect from light
Freezing—Do NOT freeze (damages the preparation)
  • Keep ampoules sealed, at room temperature (15–25°C) and protected from light; never freeze.
  • It is a pre-mixed solution — no reconstitution; if diluted for infusion, prepare immediately before use.

Selected References

  • Cerebrolysin clinical literature in ischemic stroke, dementia and traumatic brain injury.
  • Reviews of brain-derived peptide preparations and neurotrophic mimetics.

Quality & Supply

  • Standardised peptide-fraction preparation with batch documentation
  • Consistency verified by peptide fingerprint and MW-distribution analysis
  • Research quantities with worldwide delivery
  • Supplied as sealed sterile ampoules

Need Cerebrolysin — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote